Clinical Trial Update: Study of OT-551 Eye Drops to Prevent or Delay Progression of Nuclear Cataracts Following Vitreous Removal [Phase 2]

View source ↗

Summary

Phase 2 study of OT-551 Eye Drops to prevent or delay progression of nuclear cataracts after vitrectomy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract
• Nuclear Cataract

Drugs mentioned

• OT-551 Eye Drops (OT-551)

Snippet

Sponsor: Othera Pharmaceuticals | Conditions: Epiretinal Membrane, Macular Hole | Phase 2 | Status: TERMINATED